Co-abuse of alprazolam augments the hepato-renal toxic effects of methylphenidate Article

Dutt, M, Dharavath, R, Kaur, T et al. (2020). Co-abuse of alprazolam augments the hepato-renal toxic effects of methylphenidate . 52(3), 216-221. 10.4103/ijp.IJP_758_19

cited authors

  • Dutt, M; Dharavath, R; Kaur, T; Kaur, N; Chopra, K; Sharma, S

authors

abstract

  • OBJECTIVE: Methylphenidate (MPH) is a first-line treatment option for attention-deficit hyperactive disorder and narcolepsy. MPH is one of the most abused psychostimulants by the adults and young population to stay awake, perform better, or improve concentration. The scanty reports say that the medical users or abusers mostly consider the administration of benzodiazepines to overcome the adverse effects, i.e., mood- and anxiety-related problems associated with MPH chronic abuse. This work aims to study the effect of alprazolam (ALZ) on MPH-associated adverse effects on liver and kidney. MATERIALS AND METHODS: Female Wistar rats (n = 58) were administered with MPH (10, 20, and 40 mg/kg) and ALZ (5, 10, and 20 mg/kg) alone and in combination for 28 days. Bodyweight, feed intake, and water intake were monitored weekly. Parameters related to liver and renal function, oxidative stress, and histopathology were performed to evaluate the toxic impacts on the liver and kidneys. RESULTS: ALZ, along with MPH, increased the serum alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, creatinine, and urea levels. The co-abuse also led to elevated oxidative stress and structural abnormalities in the liver and kidney tissues. CONCLUSION: The co-abuse of ALZ has amplified the hepato-renal toxic effects of MPH. Therefore, it is a significant concern for public safety, and their co-abuse must be restricted and discouraged.

publication date

  • May 1, 2020

Digital Object Identifier (DOI)

start page

  • 216

end page

  • 221

volume

  • 52

issue

  • 3